Trio of Phase I Studies Investigates Mesothelin-Directed CAR T-Cell Therapies.

doi:10.1158/2159-8290.cd-nw2026-0049

April 30, 2026

Trio of Phase I Studies Investigates Mesothelin-Directed CAR T-Cell Therapies.

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate novel mesothelin-targeted chimeric antigen receptor T-cell therapies for cancer treatment.
Three separate phase I studies conducted on distinct CAR T-cell therapies: SynKIR-110, UCMYM802, and M28z1XXPD1DNR.
Data presented at the American Association for Cancer Research Annual Meeting.
Findings from the studies demonstrate initial safety and efficacy for each mesothelin-targeted therapy.

Implication

Phase I studies explore mesothelin-directed CAR T-cell therapies, highlighting potential advances in cancer treatment.

Abstract

At the American Association for Cancer Research Annual Meeting, researchers presented data from three separate phase I studies investigating distinct mesothelin-targeted chimeric antigen receptor T-cell therapies: SynKIR-110, UCMYM802, and M28z1XXPD1DNR.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

A 2026 study studied this question.

synapsesocial.com/papers/69f5943c71405d493afff121 https://doi.org/10.1158/2159-8290.cd-nw2026-0049

View at Publisher

Ask AI

Bookmark

Share

Trio of Phase I Studies Investigates Mesothelin-Directed CAR T-Cell Therapies.

Key Points

Implication

Abstract

Discussion

Cite This Study

Trio of Phase I Studies Investigates Mesothelin-Directed CAR T-Cell Therapies.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading